Orthofix International NV shares plummeted 5.01% during Tuesday's intraday trading session, as the medical device maker's disappointing fourth-quarter earnings report weighed heavily on investor sentiment.
For the quarter ended December 2024, Orthofix reported earnings per share of $0.02, missing the consensus estimate of $0.06 per share. However, the company's revenue of $215.66 million surpassed expectations of $212.63 million. The earnings miss was a major disappointment for investors, despite the revenue beat.
Looking ahead, Orthofix expects full-year revenue for 2025 to range between $818 million and $826 million. Investors will closely monitor the company's performance and guidance in the coming quarters to assess its ability to regain profitability and deliver consistent earnings growth.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。